

GLOBAL ACADEMY *of* **WOMEN'S CANCER**

**EUROPEAN
HYBRID MEETING**

Simply the Best Education
you can get

14/15
APRIL
2023
MADRID
SPAIN

PRELIMINARY PROGRAMME

(updated: 19/01/2023)

CONTENT

Welcome Message	•	1
Programme at a Glance	•	2–3
Programme Friday, April 14 th	•	4–7
Programme Saturday, April 15 th	•	8–10
Executive Board	•	11
Invited Faculty	•	12–13
Floor Plan	•	14
General Information	•	15–17

Dear Colleagues and Friends,

The 1st meeting of the Global Academy of Women's Cancer was held in Vienna on October 8–9, 2021.

We welcomed nearly 700 participants to the kick-off in person and virtually. The overall feedback from attendees was overwhelmingly positive, reinforcing our belief that the format was spot on in combining all women's cancers into one educational meeting. Therefore, we held the second Global Academy event on July 8–9, 2022 in Munich, Germany.

Once again, the hybrid format with 250 participants live in Munich and another 460 participants online, were a great success for us.

In 2023, the Global Academy of Women's Cancer will meet for its 3rd International Meeting on April 14/15, 2023 in Madrid, Spain.

We invite you to attend keynote lectures, debates, Speakers Corner, Meet the Professor sessions, multidisciplinary panel discussions, case discussions, and sessions on the hot topics. During the 1.5-day meeting in Madrid, the latest results and treatment strategies will be summarized, discussed and presented by international experts.

The interactive congress offers a comprehensive overview of all new developments in breast and gynecological cancers, which account for 50% of all cancers in women, as well as direct exchange with the world's leading experts in these fields. The aim is to present the latest scientific findings in practical recommendations for everyday clinical practice.

We would like to invite you to actively participate in the event!

Join us and exchange ideas with your colleagues and experts from all over the world, broaden your knowledge and take away ideas and recommendations for your daily work.

We look forward to welcoming you in Madrid!

Andreas du Bois, MD
Scientific Chair

Jonathan Ledermann, MD
Scientific Chair

Sherko Kümmel, MD
Scientific Chair

Peter Schmid, MD
Scientific Chair

Luis Chiva, MD
Local Scientific Chair

Javier Cortes, MD
Local Scientific Chair

Antonio González-Martin, MD
Local Scientific Chair

PROGRAMME AT A GLANCE

Friday, April 14th

Madrid 1/2

Madrid 4

8:30		
9:00		
10:00	MEET THE EXPERTS SESSIONS Interactive sessions before the event	
11:00	OPENING OF THE CONFERENCE	
	JOINT LECTURE I	
12:00	SCIENTIFIC SYMPOSIUM I	
13:00	BREAK	
14:00	JOINT LECTURE II	
15:00	BREAK	
16:00	BREAST CANCER SESSION I	GYNAE-ONCOLOGY SESSION I
17:00	BREAK	
18:00	SATELLITE SYMPOSIUM I	
19:00	BREAST CANCER SESSION II	GYNAE-ONCOLOGY SESSION II

Saturday, April 15th

Madrid 1/2

Madrid 4

8:30	BREAST CANCER SESSION III	GYNAE-ONCOLOGY SESSION III
9:00		
10:00	BREAK	
	SATELLITE SYMPOSIUM II	
11:00		
	SCIENTIFIC SYMPOSIUM II	
12:00		
	BREAK	
13:00	BREAST CANCER SESSION IV	GYNAE-ONCOLOGY SESSION IV
14:00		
15:00	BREAK	
	JOINT LECTURE III	
16:00		
	CLOSING REMARKS AND FAREWELL	
17:00		
18:00		
19:00		

Friday, April 14th

10:00–11:00

MEET THE EXPERTS SESSIONS

Managing the side-effects of new drugs including immuno-oncology

Peter Schmid, London, United Kingdom

Current standard in axillary surgery: How much escalation or de-escalation is appropriate.

From surgery for local recurrence to targeted axillary dissection

Jens-Uwe Blohmer, Berlin, Germany

Selection criteria for surgery in recurrent Ovarian Cancer

Andreas du Bois, Essen, Germany

How to treat rare epithelial Ovarian Cancer

Jonathan Ledermann, London, United Kingdom

11:00

WELCOME

11:15–12:15 | Madrid 1/2

JOINT LECTURE I

MY PERSONAL HIGHLIGHTS OF 2022

CHAIRS: ANTONIO GONZALEZ MARTIN, MADRID, SPAIN

JAVIER CORTES, BARCELONA, SPAIN

11:15–11:35 ... in Breast Cancer (clinical)

Hope S. Rugo, San Francisco, USA

11:35–11:55 ... in Breast Cancer (basic and translational)

Fabrice André, Villejuif, France

11:55–12:15 ... in Gynaecological Oncology

Nicole Concin, Innsbruck/Essen, Austria/Germany

Friday, April 14th

12:15–13:15 | Madrid 1/2

SCIENTIFIC SYMPOSIUM I CDK4/6

CDK4/6i DIFFER IN THEIR EFFICACY REGARDING SURVIVAL

CHAIRS: JAVIER CORTES, BARCELONA, SPAIN

STEVEN JOHNSTON, LONDON, UNITED KINGDOM

12:15–12:35 Pro: Yes – we have different CDK4/6 Inhibitors for survival

Nadia Harbeck, Munich, Germany

12:35–12:55 Contra: No – we don't have different CDK4/6 Inhibitors for survival

Antonio Llombart Cussac, València, Spain

12:55–13:15 Panel Discussion:

Nadia Harbeck, Munich, Germany

Miguel Martin, Madrid, Spain

Peter Schmid, London, United Kingdom

Stephen Johnston, London, United Kingdom

Antonio Llombart, Valencia, Spain

13:15–14:15

BREAK

14:15–15:15 | Madrid 1/2

JOINT LECTURE II

HEREDITARY BREAST AND GYNAE-CANCER/GENETICS

CHAIRS: JONATHAN LEDERMANN, LONDON, UNITED KINGDOM

NN

14:15–14:30 Hereditary Breast Cancer and BRCA: ESMO guidelines on risk assessment, genetic testing and clinical consequences

Shani Paluch-Shimon, Tel Aviv, Israel

14:30–14:35 Discussion

14:35–14:50 Keynote lecture: Hereditary cancer syndromes in Gynecological Oncology

Nicoletta Colombo, Milan, Italy

14:50–14:55 Discussion

14:55–15:10 Prophylactic surgery in hereditary cancer syndromes.

Isabel Rubio, Madrid, Spain

PROGRAMME

Friday, April 14th

15:15–15:45

BREAK

15:45–17:15 | Madrid 1/2

BREAST CANCER SESSION I

ADJUVANT THERAPY IN HR-POSITIVE
BREAST CANCER

CHAIRS: ANTONIO LLOMBART CUSSAC,
VALENCIA, SPAIN
MIGUEL MARTIN, MADRID, SPAIN

KEYNOTE LECTURES

- 15:45–16:05 Optimal endocrine therapy
Michael Gnant, Vienna, Austria
- 16:05–16:25 Who benefits from adjuvant CDK
4/6 inhibitors?
**Stephen Johnston, London, United
Kingdom**
- 16:25–16:45 Who benefits from adjuvant
chemotherapy in ER+ Breast
Cancer?
Nadia Harbeck, Munich, Germany

CASE DISCUSSION

- 16:45–17:00 Premenopausal ER+ breast cancer
– ovarian suppression, fertility and
pregnancy
Alessandra Gennari, Genova, Italy
- 17:00–17:15 Discussion

15:45–17:15 | Madrid 4

GYNAE-ONCOLOGY SESSION I

CERVICAL CANCER

CHAIRS: MANSOOR RAZA MIRZA,
COPENHAGEN, DENMARK
NICOLETTA COLOMBO,
MILAN, ITALY

DEBATE Cervical Cancer FIGO IB – which
surgical approach/technique for
whom

- 15:45–16:05 Open radical hysterectomy
**David Cibula, Prague,
Czech Republic**
- 16:05–16:25 Laparoscopic hysterectomy
Luis Chiva, Madrid, Spain
- 16:25–16:45 Simple hysterectomy
Marie Plante, Quebec, Canada
- 16:45–17:00 Discussion

CASE DISCUSSION

- 17:00–17:15 Recurrent cervical cancer after
radio chemotherapy
Nicoletta Colombo, Milan, Italy

17:15–17:45

BREAK

17:45–18:45 | Madrid 1/2

SATELLITE SYMPOSIUM I

Friday, April 14th

18:45–19:45 | Madrid 1/2

BREAST CANCER SESSION II

EBC – TNBC

CHAIRS: JAVIER CORTES, BARCELONA, SPAIN
SHERKO KÜMMEL, ESSEN, GERMANY

18:45–19:05 Update on treatment of early TNBC
**Peter Schmid, London,
United Kingdom**

DEBATE

19:05–19:45 Should we escalate or de-escalate
depending on response to neoadju-
vant chemo plus CIT in eTNBC? Role
of adjuvant CIT and/or treatment/
combination with capecitabine/
PARPi

19:05–19:15 Pro
Rebecca Dent, Singapore

19:15–19:25 Contra
Giuseppe Curigliano, Milan, Italy

19:25–19:45 Panel Discussion
Rebecca Dent, Singapore
**Shaheenah Dawood, Dubai,
United Arab Emirates**
**Peter Schmid, London,
United Kingdom**
Giuseppe Curigliano, Milan, Italy
**Oleg Gluz, Moenchengladbach,
Germany**

18:45–19:45 | Madrid 4

GYNAE-ONCOLOGY SESSION II

ENDOMETRIAL CANCER

CHAIRS: NICOLETTA COLOMBO, MILAN, ITALY
MARIE PLANTE, QUEBEC, CANADA

KEYNOTE LECTURES

18:45–19:00 Precision adjuvant therapy in
Endometrial Cancer
David Tan, Singapore

19:00–19:15 Actual status of immuno-oncology
in Endometrial Cancer
**Mansoor Raza Mirza,
Copenhagen, Denmark**

19:15–19:30 Targeted therapy beyond immuno-
oncology in Endometrial Cancer
**Jose Alejandro Perez-Fidalgo,
Valencia, Spain**

19:30–19:45 Discussion

Saturday, April 15th

08:30–10:00 | Madrid 1/2

BREAST CANCER SESSION III

EBC HER2+

CHAIRS: JAVIER CORTES, BARCELONA, SPAIN
NN

LECTURE

08:30–08:50 Update on treatment of HER2+ EBC
Sara Tolaney, Boston, USA

08:50–09:00 Discussion

CASE DISCUSSION

09:00–09:40 Can we escalate or de-escalate depending on response to neoadjuvant HER2-targeted therapy? Role of shorter vs longer chemotherapy + HER2-blockade and/or adjuvant HER2-targeted therapy

09:00–09:10 Pro:
Sherko Kümmel, Essen, Germany

09:10–09:20 Contra:
Carlos Barrios, Porto Alegre, Brazil

09:20–09:40 Panel Discussion
Nadia Harbeck, Munich, Germany
Carlos Barrios, Porto Alegre, Brazil
Sherko Kümmel, Essen, Germany
Giuseppe Curigliano, Milan, Italy

KEYNOTE LECTURE

09:40–10:00 Clinical practice and research activities: how to integrate them into everyday life
Javier Cortes, Barcelona, Spain

08:30–10:00 | Madrid 4

GYNAE-ONCOLOGY SESSION III

SURGICAL QUESTIONS IN GYNECOLOGICAL ONCOLOGY

CHAIRS: LUIS CHIVA, MADRID, SPAIN
NICOLE CONCIN, INNSBRUCK/ESSEN, AUSTRIA/GERMANY

DEBATE

Complete clinical/radiological remission after 4 courses of neoadjuvant treatment of ovarian cancer. What to do?

08:30–8:40 Open IDS
NN

8:40–08:50 Laparoscopic IDS
Christian Marth, Innsbruck, Austria

08:50–09:00 No surgery necessary
Ignacio Romero Noguera, Valencia, Spain

09:00–09:10 Discussion

CASE DISCUSSION

09:10–09:30 Case 1: Management of FIGO 4
Andreas du Bois, Essen, Germany

09:30–09:35 Discussion

09:35–09:55 Case 2: Minor response after NACT: IDS or not?
Christina Fotopoulou, London, United Kingdom

09:55–10:00 Discussion

10:00–10:15

BREAK

10:15–11:15 | Madrid 1/2

SATELLITE SYMPOSIUM II

Saturday, April 15th

11:15–12:00 | Madrid 1/2

SCIENTIFIC SYMPOSIUM II SERD'S

CHAIR: JAVIER CORTES, BARCELONA, SPAIN

- 11:15–11:30 Do we need SERD's
Aditya Bardia, Boston, USA
- 11:30–11:45 2ndline (hormone) treatment options after CDK4/6
Hope S. Rugo, San Francisco, USA
- 11:45–12:00 Endocrine Resistance at HR+ mBC – what we know?
Fabrice Andre, Villejuif, France

12:00–13:00

BREAK

13:00–14:45 | Madrid 1/2

BREAST CANCER SESSION IV

METASTATIC BREAST CANCER

CHAIRS: NADIA HARBECK, MUNICH, GERMANY

CASE DISCUSSION

- 13:00–13:10 Optimal treatment sequences after
adjuvant CDK4/6 inhibitors
**Oleg Gluz, Moenchengladbach,
Germany**
- 13:10–13:15 Discussion

LECTURES

- 13:15–13:25 Update on management of mTNBC
Rebecca Dent, Singapore
- 13:25–13:35 Update on management of ER+ MBC
Aditya Bardia, Massachusetts, USA
- 13:35–13:45 Update on management of HER2+
MBC
Sara Tolany, Boston, USA
- 13:45–14:05 Discussion

DEBATE

- 14:05–14:45 CNS disease – Should we prioritise
systemic therapy or radiotherapy?
- 14:05–14:20 Pro: Systemic therapy
Carlos Barrios, Porto Alegre, Brazil
- 14:20–14:35 Pro: Radiotherapy
David Krug, Keel, Germany
- 14:35–14:45 Discussion

13:00–14:45 | Madrid 4

GYNAE-ONCOLOGY SESSION IV

SYSTEMIC TREATMENT OF OVARIAN CANCER

CHAIRS: ANDREAS DU BOIS, ESSEN, GERMANY
DAVID TAN, SINGAPORE

DEBATE

- 13:00–13:45 Do we need HRD testing?
- 13:00–13:15 Pro:
**Jonathan Ledermann,
London, United Kingdom**
- 13:15–13:30 Contra:
**Antonio Gonzalez-Martin, Madrid,
Spain**

13:30–13:45 Discussion

KEYNOTE LECTURES

- 13:45–14:00 Treatment of recurrent ovarian can-
cer after PARPi
Amit Oza, Toronto, Canada

CASE DISCUSSION

- 14:00–14:20 Case 4: ROC: During maintenance
after Paola-like maintenance regi-
men with BEV+ PARPi and platinum
free interval of 8 months
David Tan, Singapore
- 14:20–14:25 Discussion

Saturday, April 15th

14:45–15:15

BREAK

15:15–16:45 | Madrid 1/2

JOINT LECTURE III

PRECISION MEDICINE AND NEW DEVELOPMENTS

CHAIRS: AMIT OZA, TORONTO, CANADA

SHAHEENAH DAWOOD, DUBAI, UNITED ARAB EMIRATES

15:15–15:30 Quality of Life during PARPi treatment

Maria Pilar Barretina Ginesta, Girona, Spain

15:30–15:35 Discussion

15:35–15:50 New drugs, new toxicities, new challenges

Antonio Gonzalez-Martin, Madrid, Spain

15:50–15:55 Discussion

15:55–16:10 Liquid Biopsy in Breast Cancer – Current Indications and Future Applications

NN

16:10–16:15 Discussion

16:15–16:30 Breast Cancer: Integrating molecular pathology and personalised medicine into routine daily patient treatment

Fabrice André, Villejuif, France

16:30–16:45 Discussion

16:45

CLOSING REMARKS AND FAREWELL

Initiators of the Global Academy of Women's Cancer

Andreas du Bois, MD
Essen, Germany

Jonathan Ledermann, MD
London, United Kingdom

Sherko Kümmel, MD
Essen, Germany

Peter Schmid, MD
London, United Kingdom

Scientific Board Gynaecological Oncology

Nicoletta Colombo, MD
Milan, Italy

Amit Oza, MD
Toronto, Canada

**Antonio
González-Martin, MD**
Madrid, Spain

David Tan, MD
Singapore

Scientific Board Breast Cancer

Carlos Barrios, MD
Rio de Janeiro, Brazil

Rebecca Dent, MD
Singapore

Javier Cortes, MD
Barcelona, Spain

Nadia Harbeck, MD
Munich, Germany

Fabrice André

Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France
fabrice.andre@gustaveroussy.fr

Aditya Bardia

Mass General Cancer Center:
Hematology Oncology
55 Fruit St.
Boston, MA 02114
bardia.aditya@mg.harvard.edu

Maria Pilar Barretina Ginesta

ICO Girona – Hospital Universitario
Doctor Josep Trueta
Avenida França s/n
17007 Girona, Spain
mpbarretina@iconcologia.net

Carlos Barrios

Oncoclínicas Group
Oncology Research Center, São Lucas
Hospital, PUCRS
Latin American Cooperative Oncology
Group (LACOG)
Coroados 837
Porto Alegre RS 9190580 Brazil
barrios@tummi.org

Jens-Uwe Blohmer

Campus Charité Mitte
Anschrift: Charitéplatz 1
10117 Berlin, Germany
jens.blohmer@charite.de

Andreas du Bois

Evang.Kliniken Essen-Mitte
Huyssens-Stiftung Essen-Huttrop
Klinik für Gynäkologie und
Gynäkologische Onkologie
Henricistr. 92
45136 Essen, Germany

Luis Chiva

Clínica Universidad de Navarra
Marquesado de Santa Marta Street 1
28027, Madrid, Spain
lchiva@unav.es

David Cibula

Charles University and General
University Hospital
First Faculty of Medicine
LF UK Praha
Kateřinská 32
121 08 Prague 2

Nicoletta Colombo

Divisione di Ginecologia Oncologia
Medica
IRCCS Istituto Europeo di Oncologia
Via Ripamonti 435
20144 Milan, Italy
nicoletta.colombo@ieo.it

Nicole Concin

Evang. Kliniken Essen-Mitte
Essen, Germany
University of Innsbruck
Innsbruck, Austria
n.concin@kem-med.com
nicole.concin@i-med.ac.at

Javier Cortes

Vall d'Hebron Institute of Oncology
Centro Cellex, Carrer de Natxaret,
115-117
08035 Barcelona, Spain
jacortes@vhio.net

Giuseppe Curigliano

University of Milan
Via Ripamonti, 435 – IEO – Istituto
Europeo di Oncologia
20141 Milan, Italy
giuseppe.curigliano@unimi.it

Shaheenah Dawood

Mediclinic Middle East
Dubai Healthcare City, Bldg 37
Dubai, United Arab Emirates

Rebecca Dent

National Cancer Center Singapore
11 Hospital Cres
Singapore 169610
rebecca.dent@singhealth.com

Christina Fotopoulou

Imperial College London
Hammersmith Hospital
Du Cane Road, W12 7BH
London, UK
christina.fotopoulou@nhs.net

Alessandra Gennari

Maggiore Hospital Novara
Corso Mazzini n. 18
28100 Novara, Italy
alessandra.gennari@med.uniupo.it

Michael Gnant

Medizinische Universität Wien
Brustgesundheitszentrum
Waehringer Guertel 18-20
1090 Vienna, Austria
michael.gnant@meduniwien.ac.at

Oleg Gluz

Brustzentrum Niederrhein
Ludwig-Weber-Straße 15
41061 Mönchengladbach, Germany
oleg.gluz@wsg-online.com

Antonio González-Martin

Servicio de Oncología Medica
Clinica Universidad de Navarra
Avenida P o XII, 36
31008 Madrid, Spain
agonzalezma@unav.es

Nadia Harbeck

Frauenkliniken Großhadern und
Maistrasse-Innenstadt
Brustzentrum der Universität
München
Marchioninstr. 15
81377 Munich, Germany
nadia.harbeck@med.uni-muenchen.de

Sara A. Hurvitz

Santa Monica Parkside Cancer Care
2336 Santa Monica Boulevard
Suite 304
Santa Monica, California 90404
shurvitz@mednet.ucla.edu

Stephen Johnston

The Royal Marsden NHS
Foundation Trust & The Institute
of Cancer Research,
Fulham Road, Chelsea, London,
SW3 6JJ, United Kingdom
stephen.johnston@rmh.nhs.uk

Sherko Kümmel

Evang.Kliniken Essen-Mitte
Huyssens-Stiftung Essen-Hutrop
Klinik für Senologie/Brustzentrum
Henricistr. 92
45136 Essen, Germany
s.kuettel@kliniken-essen-mitte.de

Jonathan Ledermann

Clinical Director
UCL Cancer Institute
Department of Oncology
72 Huntley Street,
London WC1E 6DD
United Kingdom
j.ledermann@ucl.ac.uk

Antonio Llombart Cussac

Arnau de Vilanova Hospital
of Valencia
Carrer de Sant Clement, 12
46015 València, Spain

Christian Marth

Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie
und Geburtshilfe
Anichstr. 35
6020 Innsbruck, Austria
christian.marth@i-med.ac.at

Miguel Martin

Hospital General Universitario
Gregorio Marañón
C. del Dr. Esquerdo, 46
28007 Madrid, Spain

Mansoor Raza Mirza

Nordic Society of Gynaecological
Oncology
Dept. of Oncology
9431 Rigshospitalet
Copenhagen University Hospital
Blegdamsvej 9
2100 Copenhagen, Denmark
mansoor.raza.mirza@regionh.dk

Ignacio Romero Noguera

Centro Oncológico Integral
Quirónsalud Valencia Day Hospital
C/ Blasco Ibáñez, 14
46010 Valencia, Spain

Amit Oza

Ontario Institute for Cancer Research
MaRS Centre
661 University Avenue, Suite 510
Toronto, Ontario Canada, M5G OA3
amit.oza@uhn.ca

Shani Paluch-Shimon

Hadassah University Hospital
Kiryat Hadassah
Jerusalem 91120, Israel

Melissa Phillips

Center for Molecular Oncology
Barts Cancer Institute
Charterhouse Square, London
EC1M 5PZ
United Kingdom

Marie Plante

Department of Obstetrics,
Gynecology, and Reproduction
Faculty of Medicine, Université Laval
L'Hôtel-Dieu de Québec
11, côte du Palais
Québec, G1R 2J6, Canada

Jose Alejandro Perez-Fidalgo

Servicio de Oncología
Hospital Clínico Universitario
de Valencia
Avenida Blasco Ibáñez, 17
46010 Valencia, Spain

Isabel Rubio

Cancer Center Universidad
de Navarra
C. del Marquesado de Sta. Marta, 1
28027 Madrid, Spain

Hope S. Rugo

University of California San Francisco
UCSF Helen Diller Family
Comprehensive Cancer Center
1450 3rd St.
San Francisco, CA 94158

Peter Schmid

Barts Cancer Institute
Charterhouse Square Campus
Charterhouse Square
London EC1M 5PZ, United Kingdom
p.schmid@qmul.ac.uk

David Tan

Cancer Science Institute (CSI)
14 Medical Dr,
#12-01 Centre for Translational
Medicine
Singapore 117599
david_sp_tan@nuhs.edu.sg


Sara M. Tolaney

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215, USA
Sara_Tolaney@dfci.harvard.edu

FLOORPLAN

Room Plan

4th Floor



CME Credits

An application will be made.

How to receive your CME Credits

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey, received by email.

Congress Date

April 14th – April 15th, 2023

Congress Organization



Gesellschaft für medizinische Projekte mbH



Project Manager:

Mrs. Beatrice Schröder

E-Mail: beatrice.schroeder@medconcept.org

Friedenstr. 58

15366 Neuenhagen bei Berlin, Germany

Phone: +49 (0)3342 42689-13

Fax: +49 (0)3342 42689-40

E-Mail: info@medconcept.org

Internet: www.medconcept.org

Congress Website

<http://www.global-academy-of-womens-cancer.org>

Congress Venue

HOTEL RIU PLAZA ESPAÑA

BuildingC/ Gran Vía, 84

28013 Madrid

Spain

GENERAL INFORMATION

Exhibition

A commercial exhibition will be held at the congress venue, close to the main meeting room.

Exhibition Opening Hours

Friday, April 14th, 2023: 11:30–18:30

Saturday, April 15th, 2023: 09:00–17:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration Fees

Face-to-face Participation

Full Delegate – Face to Face EUR 250,00

Resident / Student / Nurse - Face to Face* EUR 100,00

*Proof by employer/university/clinic must be uploaded during the registration process.

The registration fee includes:

For participants to the face-to-face event: Access to all scientific sessions including satellite symposia and live exhibition. Access to the on-demand Service with recorded congress sessions after the congress. All conference materials will be distributed onsite. No material will be sent before the event.

Online Participation

Full Delegate - Virtual EUR 250,00

Resident / Student / Nurse – Virtual* EUR 100,00

*Proof by employer/university/clinic must be uploaded during the registration process.

The registration fee includes:

For participants to the virtual event: Access to all live scientific sessions including satellite symposia. Access to the on-demand sessions and the virtual exhibition.

Tickets: <https://global-academy-of-womens-cancer.org/registration>

Registration and Information Desk

Registration is on the 4th floor of the hotel's event area directly in front of the entrance to the meeting rooms.

Registration Desk Opening Hours

Thursday, April 13th, 2023 17:00–19:00 (early check-in)

Friday, April 14th, 2023 10:00–19:00

Saturday, April 15th, 2023 07:30–17:00

SPONSORS

Platinum



Gold



PLATINUM: 120,000 EURO
GOLD: 90,000 EURO
SILVER: 50,000 EURO
BRONZE: 30,000 EURO

Silver



Bronze



IMPORTANT INFORMATION

Certificate of Attendances

All registered attendees will receive a certificate of attendance some days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.